Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Dren Bio
Wake Forest University Health Sciences
National Institutes of Health Clinical Center (CC)
AVM Biotechnology Inc
Children's Hospital of Philadelphia
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Arovella Therapeutics Ltd
St. Justine's Hospital
Georgetown University
Eastern Cooperative Oncology Group
Medical College of Wisconsin
CRISPR Therapeutics
AstraZeneca
AvenCell Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute
University of Chicago
Vironexis Biotherapeutics Inc.
Memorial Sloan Kettering Cancer Center
Karolinska University Hospital
Assistance Publique - Hôpitaux de Paris
City of Hope Medical Center
Assistance Publique - Hôpitaux de Paris
University of Nebraska
Pfizer
Thomas Jefferson University
Fate Therapeutics
The Children's Hospital of Zhejiang University School of Medicine
Syndax Pharmaceuticals
Center for International Blood and Marrow Transplant Research
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
M.D. Anderson Cancer Center
Allogene Therapeutics
BeOne Medicines
University of Chicago
H. Lee Moffitt Cancer Center and Research Institute
Penn State University
Columbia University
Ossium Health, Inc.
Ossium Health, Inc.
Zhejiang University
University of Miami